Fosun Pharmaceutical’s HanDaYuan Seeks NMPA Approval for Expanded Indications in Autoimmune Treatments
Shanghai Fosun Pharmaceutical (Group) Co., Ltd (SHA: 600196, HKG: 2196) has announced that the National...
CDE Streamlines Patent Dispute Resolution for Generic Drug Filings with New Online Submission Process
The Center for Drug Evaluation (CDE) has announced a new initiative aimed at enhancing the...
Jiangsu Hengrui Receives NMPA Approval for HRS-1167 Clinical Trials in Advanced Solid Tumors
Jiangsu Hengrui Pharmaceutical Co., Ltd (SHA: 600276) has secured clinical trial approval from the National...
Innovent Biologics Launches Phase I Study for IBI3002, a Bispecific Antibody Targeting Asthma
Innovent Biologics, Inc. (HKG: 1801), based in China, has announced the initiation of its Phase...
CDE Grants Priority Review to Jiu An’s Adrenaline and AnHeart’s Taletrectinib; Two Others Earn Breakthrough Therapy Designation
The Center for Drug Evaluation (CDE) has announced that Jiu An Pharmaceutical’s adrenaline and AnHeart...
Sandoz Agrees to $265 Million Settlement in U.S. Generic Drug Antitrust Case
Sandoz (SIX: SDZ), the Swiss-based pharmaceutical company, announced this week that its U.S. subsidiaries have...
Huadong Medicine’s MaiLi Extreme Achieves Clinical Study Milestone for Chin Retraction Treatment
China-based Huadong Medicine Co., Ltd (SHE: 000963) has announced that a Chinese clinical study for...
ARSMO Plastic Aesthetic Hospital Introduces Liquid PCL Implant GOURI in Hainan
ARSMO Plastic Aesthetic Hospital Holding Co., Ltd. has announced the inaugural application of GOURI, a...
CARsgen Therapeutics’ BCMA-targeted CAR-T Cell Therapy Approved by China’s NMPA
CARsgen Therapeutics Holdings Ltd (HKG: 2171), a specialist in chimeric antigen receptor (CAR)-T cell therapies...
Takeda Partners with Biological E to Boost Production of Dengue Vaccine QDenga
Takeda (TYO: 4502), a leading Japanese pharmaceutical company, has entered into an agreement with India-based...
FDA Withdraws Approval for Multiple Myeloma Drug Pepaxto Over Safety and Efficacy Concerns
The US Food and Drug Administration (FDA) has announced its final decision to withdraw approval...
Chia Tai Tianqing’s Anlotinib-Benmelstobart Combo Therapy Receives CDE Review for Endometrial Cancer
Chia Tai Tianqing, a renowned biopharmaceutical company based in China, has announced that the Center...
CanSino Biologics’ 13-Valent Pneumococcal Vaccine CRM197 Accepted for NMPA Review
CanSino Biologics Inc., (HKG: 6185), a leading Chinese biopharmaceutical company, has announced that the National...
Jenscare Scientific Achieves Milestone with First LuX-Valve Plus Implantation in Brazil
Jenscare Scientific Co., Ltd (HKG: 9877), a leading structural heart disease device manufacturer headquartered in...
Viatris Secures Late-Stage Programs from Idorsia with Potential for Future Asset Additions
US pharmaceutical company Viatris (NASDAQ: VTRS) has entered into a licensing agreement with Swiss drugmaker...
MicroPort CardioFlow Forecasts 31%-36% YOY Sales Growth for 2023 Driven by TAVI Product Expansion
MicroPort CardioFlow Medtech Co., Ltd (HKG: 2160), a spin-off from China-based MicroPort Scientific Corp (HKG:...
HutchMed’s 2023 Financials Show 102% YOY Revenue Growth and Robust Collaboration with Takeda
HutchMed (HKG: 0013, NASDAQ: HCM), a China-based biopharmaceutical company, has released its financial report for...
Angitia Bio Secures USD 40 Million in Series B+ Financing to Advance Musculoskeletal Disorder Therapies
Angitia Biopharmaceuticals, a Guangzhou-based developer of therapies for bone, joint, and muscle diseases, has announced...
BMS Taps into Circular RNA Potential with Shanghai Circode Bio Agreement
Shanghai Circode Bio has entered into a feasibility study cooperation agreement with US pharmaceutical giant...
AbbVie Partners with OSE Immunotherapeutics to Develop First-in-Class Immunotherapy OSE-230
AbbVie (NYSE: ABBV) has entered into a strategic partnership with France-based OSE Immunotherapeutics (EPA: OSE)...